Cargando…
Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501688/ https://www.ncbi.nlm.nih.gov/pubmed/36159842 http://dx.doi.org/10.3389/fimmu.2022.1001444 |
_version_ | 1784795535145697280 |
---|---|
author | Yang, Zhengyang Wu, Guocong Zhang, Xiao Gao, Jiale Meng, Cong Liu, Yishan Wei, Qi Sun, Liting Wei, Pengyu Bai, Zhigang Yao, Hongwei Zhang, Zhongtao |
author_facet | Yang, Zhengyang Wu, Guocong Zhang, Xiao Gao, Jiale Meng, Cong Liu, Yishan Wei, Qi Sun, Liting Wei, Pengyu Bai, Zhigang Yao, Hongwei Zhang, Zhongtao |
author_sort | Yang, Zhengyang |
collection | PubMed |
description | Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to the mutation pattern, which is categorized into deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H) and proficient mismatch repair (pMMR), or non-high levels of microsatellite instability (non-MSI-H). PD-1/PD-L1 inhibitors have been proven to have favorable outcomes against dMMR/MSI-H CRC because of more T-cell infiltration into tumor tissues. Nevertheless, the effectiveness of PD-1/PD-L1 inhibitors in pMMR/non-MSI-H CRC is still uncertain. Because of the quite-lower proportion of dMMR/MSI-H in CRC, PD-1/PD-L1 inhibitors have been reported to combine with other antitumor treatments including chemotherapy, radiotherapy, and targeted therapy for better therapeutic effect in recent clinical trials. Neoadjuvant therapy, mainly including chemotherapy and radiotherapy, not only can reduce clinical stage but also benefit from local control, which can improve clinical symptoms and the quality of life. Adding immunotherapy into neoadjuvant therapy may change the treatment strategy of primary resectable or some metastatic CRC. In this review, we focus on the development of neoadjuvant anti-PD-1/PD-L1 therapy and discuss the future perspectives in CRC. |
format | Online Article Text |
id | pubmed-9501688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95016882022-09-24 Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer Yang, Zhengyang Wu, Guocong Zhang, Xiao Gao, Jiale Meng, Cong Liu, Yishan Wei, Qi Sun, Liting Wei, Pengyu Bai, Zhigang Yao, Hongwei Zhang, Zhongtao Front Immunol Immunology Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to the mutation pattern, which is categorized into deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H) and proficient mismatch repair (pMMR), or non-high levels of microsatellite instability (non-MSI-H). PD-1/PD-L1 inhibitors have been proven to have favorable outcomes against dMMR/MSI-H CRC because of more T-cell infiltration into tumor tissues. Nevertheless, the effectiveness of PD-1/PD-L1 inhibitors in pMMR/non-MSI-H CRC is still uncertain. Because of the quite-lower proportion of dMMR/MSI-H in CRC, PD-1/PD-L1 inhibitors have been reported to combine with other antitumor treatments including chemotherapy, radiotherapy, and targeted therapy for better therapeutic effect in recent clinical trials. Neoadjuvant therapy, mainly including chemotherapy and radiotherapy, not only can reduce clinical stage but also benefit from local control, which can improve clinical symptoms and the quality of life. Adding immunotherapy into neoadjuvant therapy may change the treatment strategy of primary resectable or some metastatic CRC. In this review, we focus on the development of neoadjuvant anti-PD-1/PD-L1 therapy and discuss the future perspectives in CRC. Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9501688/ /pubmed/36159842 http://dx.doi.org/10.3389/fimmu.2022.1001444 Text en Copyright © 2022 Yang, Wu, Zhang, Gao, Meng, Liu, Wei, Sun, Wei, Bai, Yao and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yang, Zhengyang Wu, Guocong Zhang, Xiao Gao, Jiale Meng, Cong Liu, Yishan Wei, Qi Sun, Liting Wei, Pengyu Bai, Zhigang Yao, Hongwei Zhang, Zhongtao Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer |
title | Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer |
title_full | Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer |
title_fullStr | Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer |
title_full_unstemmed | Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer |
title_short | Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer |
title_sort | current progress and future perspectives of neoadjuvant anti-pd-1/pd-l1 therapy for colorectal cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501688/ https://www.ncbi.nlm.nih.gov/pubmed/36159842 http://dx.doi.org/10.3389/fimmu.2022.1001444 |
work_keys_str_mv | AT yangzhengyang currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT wuguocong currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT zhangxiao currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT gaojiale currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT mengcong currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT liuyishan currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT weiqi currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT sunliting currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT weipengyu currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT baizhigang currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT yaohongwei currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer AT zhangzhongtao currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer |